Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers.

Birkbak NJ, Li Y, Pathania S, Greene-Colozzi A, Dreze M, Bowman-Colin C, Sztupinszki Z, Krzystanek M, Diossy M, Tung N, Ryan PD, Garber JE, Silver DP, Iglehart JD, Wang ZC, Szuts D, Szallasi Z, Richardson AL.

Ann Oncol. 2018 Apr 1;29(4):903-909. doi: 10.1093/annonc/mdy049.

2.

Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.

Ubellacker JM, Haider MT, DeCristo MJ, Allocca G, Brown NJ, Silver DP, Holen I, McAllister SS.

Breast Cancer Res. 2017 Mar 6;19(1):23. doi: 10.1186/s13058-017-0815-8.

3.

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.

Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL.

Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8.

4.

MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy.

Neupane M, Clark AP, Landini S, Birkbak NJ, Eklund AC, Lim E, Culhane AC, Barry WT, Schumacher SE, Beroukhim R, Szallasi Z, Vidal M, Hill DE, Silver DP.

Cancer Discov. 2016 Jan;6(1):45-58. doi: 10.1158/2159-8290.CD-15-0341. Epub 2015 Nov 6.

5.

Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs.

Marquard AM, Eklund AC, Joshi T, Krzystanek M, Favero F, Wang ZC, Richardson AL, Silver DP, Szallasi Z, Birkbak NJ.

Biomark Res. 2015 May 1;3:9. doi: 10.1186/s40364-015-0033-4. eCollection 2015.

6.

BRCA1 pathway function in basal-like breast cancer cells.

Hill SJ, Clark AP, Silver DP, Livingston DM.

Mol Cell Biol. 2014 Oct;34(20):3828-42. doi: 10.1128/MCB.01646-13. Epub 2014 Aug 4.

7.

Mechanisms of BRCA1 tumor suppression.

Silver DP, Livingston DM.

Cancer Discov. 2012 Aug;2(8):679-84. doi: 10.1158/2159-8290.CD-12-0221. Epub 2012 Jul 27. Review.

8.

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.

Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL.

Cancer Discov. 2012 Apr;2(4):366-375. doi: 10.1158/2159-8290.CD-11-0206. Epub 2012 Mar 22. Erratum in: Cancer Discov. 2013 Aug;3(8):952.

9.

Chek2 DNA damage response pathway and inherited breast cancer risk.

Tung N, Silver DP.

J Clin Oncol. 2011 Oct 1;29(28):3813-5. doi: 10.1200/JCO.2011.37.1476. Epub 2011 Aug 29. No abstract available.

PMID:
21876079
10.

Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers.

Tung N, Miron A, Schnitt SJ, Gautam S, Fetten K, Kaplan J, Yassin Y, Buraimoh A, Kim JY, Szász AM, Tian R, Wang ZC, Collins LC, Brock J, Krag K, Legare RD, Sgroi D, Ryan PD, Silver DP, Garber JE, Richardson AL.

Breast Cancer Res. 2010;12(6):R95. doi: 10.1186/bcr2776. Epub 2010 Nov 16.

11.

Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.

Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, Carey LA.

Clin Cancer Res. 2010 Oct 1;16(19):4702-10. doi: 10.1158/1078-0432.CCR-10-0939. Epub 2010 Sep 21. Review.

12.

Poly ADP-ribose polymerase inhibitors: science and current clinical development.

Liu JF, Silver DP.

Curr Opin Oncol. 2010 Nov;22(6):567-72. doi: 10.1097/CCO.0b013e32833edbf8. Review.

13.

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE.

J Clin Oncol. 2010 Mar 1;28(7):1145-53. doi: 10.1200/JCO.2009.22.4725. Epub 2010 Jan 25.

14.

Complex landscapes of somatic rearrangement in human breast cancer genomes.

Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C, Natrajan R, Sieuwerts AM, Martens JW, Silver DP, Langerød A, Russnes HE, Foekens JA, Reis-Filho JS, van 't Veer L, Richardson AL, Børresen-Dale AL, Campbell PJ, Futreal PA, Stratton MR.

Nature. 2009 Dec 24;462(7276):1005-10. doi: 10.1038/nature08645.

15.

Estrogen receptor-negative breast cancer: new insights into subclassification and targeting.

Zhao JJ, Silver DP.

Clin Cancer Res. 2009 Oct 15;15(20):6309-10. doi: 10.1158/1078-0432.CCR-09-2010. Epub 2009 Oct 13.

16.

Cyclin A is redundant in fibroblasts but essential in hematopoietic and embryonic stem cells.

Kalaszczynska I, Geng Y, Iino T, Mizuno S, Choi Y, Kondratiuk I, Silver DP, Wolgemuth DJ, Akashi K, Sicinski P.

Cell. 2009 Jul 23;138(2):352-65. doi: 10.1016/j.cell.2009.04.062. Epub 2009 Jul 9.

17.

Synthetic lethality--a new direction in cancer-drug development.

Iglehart JD, Silver DP.

N Engl J Med. 2009 Jul 9;361(2):189-91. doi: 10.1056/NEJMe0903044. Epub 2009 Jun 24. No abstract available.

PMID:
19553640
18.

Cancer: crossing over to drug resistance.

Livingston DM, Silver DP.

Nature. 2008 Feb 28;451(7182):1066-7. doi: 10.1038/4511066a. No abstract available.

PMID:
18305536
19.

Further evidence for BRCA1 communication with the inactive X chromosome.

Silver DP, Dimitrov SD, Feunteun J, Gelman R, Drapkin R, Lu SD, Shestakova E, Velmurugan S, Denunzio N, Dragomir S, Mar J, Liu X, Rottenberg S, Jonkers J, Ganesan S, Livingston DM.

Cell. 2007 Mar 9;128(5):991-1002.

20.

Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.

Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, Hingorani SR, Zaks T, King C, Jacobetz MA, Wang L, Bronson RT, Orkin SH, DePinho RA, Jacks T.

Cancer Cell. 2004 Apr;5(4):375-87.

21.

Association of BRCA1 with the inactive X chromosome and XIST RNA.

Ganesan S, Silver DP, Drapkin R, Greenberg R, Feunteun J, Livingston DM.

Philos Trans R Soc Lond B Biol Sci. 2004 Jan 29;359(1441):123-8.

22.

HIN-1 and the nosology of breast cancer.

Silver DP.

Cancer Biol Ther. 2003 Sep-Oct;2(5):564-5. No abstract available.

PMID:
14614328
23.

BRCA1 supports XIST RNA concentration on the inactive X chromosome.

Ganesan S, Silver DP, Greenberg RA, Avni D, Drapkin R, Miron A, Mok SC, Randrianarison V, Brodie S, Salstrom J, Rasmussen TP, Klimke A, Marrese C, Marahrens Y, Deng CX, Feunteun J, Livingston DM.

Cell. 2002 Nov 1;111(3):393-405.

24.

p16(INK4a) and p53 deficiency cooperate in tumorigenesis.

Sharpless NE, Alson S, Chan S, Silver DP, Castrillon DH, DePinho RA.

Cancer Res. 2002 May 15;62(10):2761-5.

25.
26.

p19ARF targets certain E2F species for degradation.

Martelli F, Hamilton T, Silver DP, Sharpless NE, Bardeesy N, Rokas M, DePinho RA, Livingston DM, Grossman SR.

Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4455-60. Epub 2001 Mar 27.

27.

Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells.

Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM, Scully R.

Mol Cell. 1998 Sep;2(3):317-28.

28.

Localization, interaction, and RNA binding properties of the V(D)J recombination-activating proteins RAG1 and RAG2.

Spanopoulou E, Cortes P, Shih C, Huang CM, Silver DP, Svec P, Baltimore D.

Immunity. 1995 Dec;3(6):715-26.

29.

Functional immunoglobulin transgenes guide ordered B-cell differentiation in Rag-1-deficient mice.

Spanopoulou E, Roman CA, Corcoran LM, Schlissel MS, Silver DP, Nemazee D, Nussenzweig MC, Shinton SA, Hardy RR, Baltimore D.

Genes Dev. 1994 May 1;8(9):1030-42.

30.

Dispensable sequence motifs in the RAG-1 and RAG-2 genes for plasmid V(D)J recombination.

Silver DP, Spanopoulou E, Mulligan RC, Baltimore D.

Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6100-4.

Supplemental Content

Loading ...
Support Center